In conclusion, although identified BRAFnon-V600E mutations were rare and unestablished molecular subtype in mCRC, overall clinical outcomes of BRAFnon-V600E mutations in the kinase domain, similar to those of RAS- and BRAFV600E-mutant tumours, appeared to be significantly worse than those in wild-type RAS/BRAF tumours. This evidence concerns the gene BRAF and neoplasm.